^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    MLH1 (MutL homolog 1)

    i
    Apply
    Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (NCT02912559)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/16/2017
    Primary completion :
    04/02/2025
    Completion :
    04/02/2025
    MLH1 • MSH6 • MSH2 • CD4
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (NCT02997228)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/19/2018
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    PD-L1 • MSI • MLH1 • MSH6 • MSH2
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    Precision-Based Genomics in Prostate Cancer (NCT04706663)
    Phase N/A
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/14/2021
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM
    |
    TMB-H
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (NCT05419011)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    05/08/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients (NCT05078866)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/10/2022
    Primary completion :
    07/31/2025
    Completion :
    07/31/2025
    BRAF • MSI • MLH1 • MSH6 • MSH2
    |
    BRAF mutation
    |
    NOUS-209
    Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (NCI-2017-02296) (NCT03375307)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/03/2020
    Primary completion :
    12/16/2025
    Completion :
    12/16/2025
    TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC
    |
    FANCG mutation
    |
    Lynparza (olaparib)
    Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (NRG-GY025) (NCT05112601)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/18/2025
    Initiation :
    06/02/2022
    Primary completion :
    04/30/2026
    Completion :
    04/30/2026
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer (NCT05836584)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/06/2023
    Primary completion :
    10/31/2027
    Completion :
    10/31/2027
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • docetaxel • capecitabine • oxaliplatin • leucovorin calcium • fluorouracil topical
    Stand Up to Cancer: MAGENTA (Making Genetic Testing Accessible) (NCT02993068)
    Phase N/A
    M.D. Anderson Cancer Center
    Suspended
    Last update posted :
    02/12/2025
    Initiation :
    04/18/2017
    Primary completion :
    04/18/2026
    Completion :
    04/18/2026
    ER • PGR • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1
    |
    PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    Pancreatic Cancer Early Detection Consortium (PRECEDE) (NCT04970056)
    Phase N/A
    Arbor Research Collaborative for Health
    Recruiting
    Last update posted :
    02/11/2025
    Initiation :
    09/18/2020
    Primary completion :
    12/31/2030
    Completion :
    12/31/2030
    BRCA1 • BRCA2 • STK11 • CDKN2A • MLH1 • MSH6 • MSH2
    Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases (NCT03844750)
    Phase 2
    Chloe Atreya, MD, PhD
    Active, not recruiting
    Last update posted :
    02/11/2025
    Initiation :
    07/22/2019
    Primary completion :
    04/30/2026
    Completion :
    04/30/2026
    PD-L1 • MLH1 • MSH6 • MSH2
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • vactosertib (TEW-7197)
    Men at High Genetic Risk for Prostate Cancer (NCT03805919)
    Phase N/A
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/10/2025
    Initiation :
    03/27/2019
    Primary completion :
    01/01/2029
    Completion :
    01/01/2039
    TP53 • BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD51D • EPCAM • NBN • FANCF • FANCL • FANCI • FANCM • FANCD2 • FANCE • FANCG • FANCB • FANCC • HOXB13
    Metagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes (NCT02371135)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Active, not recruiting
    Last update posted :
    02/04/2025
    Initiation :
    02/01/2015
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    STK11 • MLH1 • MSH6 • MSH2 • SMAD4 • APC • EPCAM • BMPR1A
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors (NCT04126070)
    Phase 2
    Xiao X. Wei, MD
    Active, not recruiting
    Last update posted :
    01/29/2025
    Initiation :
    05/11/2020
    Primary completion :
    10/24/2024
    Completion :
    06/30/2025
    PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension
    Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer (NCT05999812)
    Phase 2
    University of Texas Southwestern Medical Center
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    12/19/2023
    Primary completion :
    10/01/2026
    Completion :
    10/01/2028
    BRAF • MSI • MLH1 • MSH6 • MSH2 • CD4
    |
    BRAF V600E • BRAF V600 • RAS wild-type
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab)
    Evaluation of a Multimodal Strategy for Early Diagnosis of Men At High Genetic Risk of Prostate Cancer (HRPCa-II) (NCT05333432)
    Phase N/A
    Assistance Publique - Hôpitaux de Paris
    Not yet recruiting
    Last update posted :
    01/28/2025
    Initiation :
    03/01/2025
    Primary completion :
    03/01/2030
    Completion :
    03/01/2030
    TP53 • BRCA1 • BRCA2 • PTEN • STK11 • MLH1 • MSH6 • MSH2 • CDH1 • CHEK2 • BRIP1 • RAD51C • RAD50 • RAD51D • BARD1 • NBN • HOXB13
    |
    PALB2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    Olaparib with or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy (OPTIMUM) (NCT05222971)
    Phase 2
    Asan Medical Center
    Recruiting
    Last update posted :
    01/28/2025
    Initiation :
    04/01/2022
    Primary completion :
    12/30/2025
    Completion :
    12/30/2026
    BRCA1 • BRCA2 • ATM • POLE • BAP1 • MLH1 • MSH6 • MSH2 • BRCA • CHEK2 • RAD51 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • XRCC2 • FANCD2 • GEN1
    |
    ATM mutation • CHEK2 mutation • BRIP1 mutation • BARD1 mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab)
    Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery (NCT04774419)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    11/11/2024
    Initiation :
    04/02/2021
    Primary completion :
    02/01/2026
    Completion :
    02/01/2026
    MSI • POLE • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • POLE mutation
    |
    Jemperli (dostarlimab-gxly)
    A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) (NCT03835819)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    11/08/2024
    Initiation :
    01/02/2020
    Primary completion :
    06/04/2024
    Completion :
    05/01/2027
    FOLR1 • MLH1 • MSH6 • MSH2
    |
    MSH6 expression
    |
    Keytruda (pembrolizumab) • Elahere (mirvetuximab soravtansine-gynx)
    Researching the Effect of Aerobic Exercise on Cancer (NCT03996239)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    06/20/2019
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    Atorvastatin ± Aspirin in Lynch Syndrome Syndrome (NCT04379999)
    Phase 1
    Fox Chase Cancer Center
    Recruiting
    Last update posted :
    06/13/2024
    Initiation :
    09/10/2018
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    MLH1 • MSH6 • MSH2 • EPCAM • CASP3
    |
    MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    atorvastatin
    Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers (NCT04082572)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    06/10/2024
    Initiation :
    09/17/2019
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab)
    Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation (NCI-2022-02494) (NCT05308446)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    07/19/2022
    Primary completion :
    08/31/2024
    Completion :
    08/31/2024
    BRAF • MSI • MLH1 • MSH6 • MSH2
    |
    BRAF V600E • BRAF V600
    |
    Opdivo (nivolumab) • Erbitux (cetuximab) • Braftovi (encorafenib) • ABP 206 (nivolumab biosimilar)
    Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations (NCT02760849)
    Phase N/A
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    06/06/2024
    Initiation :
    05/02/2016
    Primary completion :
    05/31/2041
    Completion :
    05/31/2041
    BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • BRIP1 • RAD51C • RAD51D • BARD1
    |
    BARD1 mutation
    Pancreatic Cancer Early Detection Program (PCEDP) (NCT02206360)
    Phase N/A
    White Plains Hospital
    Active, not recruiting
    Last update posted :
    05/24/2024
    Initiation :
    04/01/2014
    Primary completion :
    03/01/2024
    Completion :
    06/01/2024
    BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    TP53 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer (NCT05961709)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    05/21/2024
    Initiation :
    05/20/2024
    Primary completion :
    04/30/2026
    Completion :
    04/30/2028
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR
    |
    Libtayo (cemiplimab-rwlc)
    PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC (NCT03442569)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Active, not recruiting
    Last update posted :
    05/14/2024
    Initiation :
    03/09/2018
    Primary completion :
    09/21/2020
    Completion :
    12/22/2024
    KRAS • BRAF • MLH1 • MSH6 • MSH2
    |
    KRAS wild-type • NRAS wild-type
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Vectibix (panitumumab)
    TT-702 in Patients With Advanced Solid Tumours. (CURATE) (NCT05272709)
    Phase 1/2
    Cancer Research UK
    Recruiting
    Last update posted :
    05/13/2024
    Initiation :
    01/19/2022
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    HER-2 • ER • PGR • MSI • MLH1 • MSH6 • MSH2
    |
    HER-2 positive • HR positive • MSI-H/dMMR • HER-2 negative • ER negative
    |
    Nubeqa (darolutamide) • TT-702
    Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders (NCT04729322)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    05/02/2024
    Initiation :
    02/22/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    MSI • MLH1 • MSH6 • MSH2 • CEACAM5
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab)
    Nivolumab in Biochemically Recurrent dMMR Prostate Cancer (CA209-76M) (NCT04019964)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    04/26/2024
    Initiation :
    01/13/2020
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    TMB • MSI • MLH1 • MSH6 • MSH2 • CDK12
    |
    MSI-H/dMMR • CDK12 mutation
    |
    Opdivo (nivolumab)
    Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer (NCT02912572)
    Phase 2
    Dana-Farber Cancer Institute
    Active, not recruiting
    Last update posted :
    04/19/2024
    Initiation :
    11/14/2016
    Primary completion :
    03/01/2025
    Completion :
    03/01/2027
    MSI • POLE • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • POLE mutation • MSH6 expression
    |
    Bavencio (avelumab) • Talzenna (talazoparib) • Inlyta (axitinib)
    Quebec Pancreas Cancer Study (QPCS) (NCT04104230)
    Phase N/A
    George Zogopoulos
    Recruiting
    Last update posted :
    04/17/2024
    Initiation :
    03/12/2012
    Primary completion :
    01/01/2025
    Completion :
    01/01/2025
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1
    |
    ATM mutation • STK11 mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • MLH1 mutation • PMS2 mutation
    A Pancreatic Cancer Screening Study in Hereditary High Risk Individuals (NCT03250078)
    Phase N/A
    Nuvance Health
    Recruiting
    Last update posted :
    04/01/2024
    Initiation :
    11/01/2016
    Primary completion :
    11/01/2026
    Completion :
    11/01/2026
    BRCA1 • BRCA2 • CDKN2A • MLH1 • MSH6 • MSH2
    |
    BRCA1 mutation • ATM mutation • PALB2 mutation • CDKN2A mutation • MSH2 mutation • PMS2 mutation
    Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (SU2C ACT3) (NCT03803553)
    Phase 3
    Massachusetts General Hospital
    Recruiting
    Last update posted :
    03/20/2024
    Initiation :
    04/16/2020
    Primary completion :
    12/01/2026
    Completion :
    12/01/2027
    BRAF • MSI • MLH1 • MSH6 • MSH2
    |
    BRAF V600E • MSI-H/dMMR • BRAF V600
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • 5-fluorouracil • Perjeta (pertuzumab) • Mektovi (binimetinib) • Braftovi (encorafenib) • irinotecan • leucovorin calcium
    A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation (CHOMP) (NCT04104893)
    Phase 2
    VA Office of Research and Development
    Recruiting
    Last update posted :
    03/20/2024
    Initiation :
    02/20/2020
    Primary completion :
    03/31/2025
    Completion :
    12/31/2025
    EGFR • MSI • MLH1 • MSH6 • MSH2 • CDK12 • PMS1
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • abiraterone acetate
    Pancreatic Cancer Screening for At-risk Individuals (PancreasScan) (NCT05006131)
    Phase N/A
    Beth Israel Deaconess Medical Center
    Recruiting
    Last update posted :
    03/19/2024
    Initiation :
    07/10/2020
    Primary completion :
    03/10/2027
    Completion :
    03/10/2028
    BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • BRCA • EPCAM • PRSS1
    |
    BRCA2 mutation • BRCA1 mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS2 mutation • BRCA mutation
    A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome (NCT05411718)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    03/13/2024
    Initiation :
    03/21/2023
    Primary completion :
    11/30/2025
    Completion :
    11/30/2025
    MSI • MLH1 • MSH6 • MSH2
    |
    MSI-H/dMMR • MSH2 mutation • MLH1 mutation • PMS2 mutation
    |
    aspirin
    Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery (NCT03396926)
    Phase 2
    University of California, San Francisco
    Completed
    Last update posted :
    03/07/2024
    Initiation :
    04/18/2018
    Primary completion :
    01/30/2024
    Completion :
    01/30/2024
    MLH1 • MSH6 • MSH2
    |
    MSH6 expression
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • capecitabine
    Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention (NCT05677048)
    Phase N/A
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    02/28/2024
    Initiation :
    04/14/2023
    Primary completion :
    10/31/2025
    Completion :
    10/31/2027
    BRCA1 • BRCA2 • MLH1 • MSH6 • MSH2 • EPCAM
    |
    BRCA1 mutation • MSH2 mutation • PMS2 mutation
    Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals (NCT06122896)
    Phase 1
    Dana-Farber Cancer Institute
    Recruiting
    Last update posted :
    02/28/2024
    Initiation :
    11/21/2023
    Primary completion :
    10/31/2040
    Completion :
    10/31/2041
    TP53 • BRCA1 • BRCA2 • ATM • STK11 • CDKN2A • MLH1 • MSH6 • MSH2 • EPCAM • PRSS1